case_images: PMC6431461_01
case_images: (a) Case 1 CT scan images at baseline and after treatment revealing persistent lymph nodes (marked by arrow) of similar size. (b) Case 1 CT scan images at baseline and after treatment revealing persistent lymph nodes (marked by arrow) of similar size. (c) Normal lymph node with no metastatic tumor present (hematoxylin and eosin stain and Mart-1-stained sections, 20x magnification).
case_images: CRIONM2019-4683531.001.jpg
case_images: PMC6431461_01_CRIONM2019-4683531.001.jpg
case_images: fig1
case_images: Four months into the trial and after 2 months of finishing ipilimumab, the patient continued to show persistent right inguinal lymph nodes with no evidence of disease progression (Figures 1(a) and 1(b)). Pathology review of all excised lymph nodes did not reveal any evidence of melanoma (0/5 Figure 1(c)).
case_images: PMC6431461_02
case_images: (a) CT images of case 2 showing persistent lymph nodes (marked by arrow) with decreased size and calcification. (b) CT images of case 2 showing persistent lymph nodes (marked by arrow) with decreased size and calcification. (c) CT images of case 2 showing persistent lymph nodes (marked by arrow) with decreased size and calcification. (d) Necrotic lymph node with infiltrating inflammatory cells and no viable tumor present (hematoxylin- and eosin-stained sections, 20x and 100x magnification).
case_images: CRIONM2019-4683531.002.jpg
case_images: PMC6431461_02_CRIONM2019-4683531.002.jpg
case_images: fig2
case_images: Two and a half years into the trial, the patient experienced partial response with persistent evidence of lymph nodes on CT scans (Figures 2(a)-2(c)). Pathology review of 11 dissected lymph nodes did not show any evidence of melanoma (Figure 2(d)).